Search research articles
Contact Us
Filters
Showing results (1-10 of 140) with videos related to
Page
of 14
Sort By:
Hepatobiliary Surgery and Nutrition
|
June 18, 2025
Rethinking portal hypertension in hepatocellular carcinoma resection: a gradient of risk beyond black and white
David Pereyra, Patrick Starlinger
Hepatology (Baltimore, Md.)
|
January 23, 2016
Reply
Patrick Starlinger, Alice Assinger
Expert Review of Gastroenterology & Hepatology
|
February 25, 2016
Importance of platelet-derived growth factors in liver regeneration
Patrick Starlinger, Alice Assinger
Annals of Surgical Oncology
|
June 27, 2026
ASO Author Reflections: Neoadjuvant Therapy and Post-Recurrence Overall Survival in Intrahepatic Cholangiocarcinoma
Yawen Dong, Patrick Starlinger
Hepatology (Baltimore, Md.)
|
January 30, 2018
Reply
David Pereyra, Patrick Starlinger
Annals of Surgical Oncology
|
May 4, 2026
ASO Author Reflections: Neoadjuvant Therapy as a Selection Strategy for Curative Resection in High-Risk Intrahepatic Cholangiocarcinoma
Yawen Dong, Patrick Starlinger
Annals of Surgical Oncology
|
August 8, 2025
ASO Author Reflections: Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Surgical Conversion in Borderline Resectable Cholangiocarcinoma
Yawen Dong, Patrick Starlinger
Hepatology (Baltimore, Md.)
|
March 27, 2014
Role of platelets in systemic tissue protection after remote ischemic preconditioning
Patrick Starlinger, Thomas Gruenberger
Journal of Hepatology
|
March 20, 2018
Reply to: "Intra-platelet serotonin in prognosis of tumorigenesis: Friend or foe?"
David Pereyra, Patrick Starlinger
Annals of Surgical Oncology
|
August 21, 2025
ASO Author Reflections: Real-World Outcomes of Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab for Surgical Conversion of Borderline Resectable Cholangiocarcinoma
Yawen Dong, Patrick Starlinger
Page
of 14
Search research articles
Search
Showing results (1-10 of 140) with videos related to
Sort By:
Page
of 14
Hepatobiliary Surgery and Nutrition
|
June 18, 2025
Rethinking portal hypertension in hepatocellular carcinoma resection: a gradient of risk beyond black and white
David Pereyra, Patrick Starlinger
Hepatology (Baltimore, Md.)
|
January 23, 2016
Reply
Patrick Starlinger, Alice Assinger
Expert Review of Gastroenterology & Hepatology
|
February 25, 2016
Importance of platelet-derived growth factors in liver regeneration
Patrick Starlinger, Alice Assinger
Annals of Surgical Oncology
|
June 27, 2026
ASO Author Reflections: Neoadjuvant Therapy and Post-Recurrence Overall Survival in Intrahepatic Cholangiocarcinoma
Yawen Dong, Patrick Starlinger
Hepatology (Baltimore, Md.)
|
January 30, 2018
Reply
David Pereyra, Patrick Starlinger
Annals of Surgical Oncology
|
May 4, 2026
ASO Author Reflections: Neoadjuvant Therapy as a Selection Strategy for Curative Resection in High-Risk Intrahepatic Cholangiocarcinoma
Yawen Dong, Patrick Starlinger
Annals of Surgical Oncology
|
August 8, 2025
ASO Author Reflections: Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Surgical Conversion in Borderline Resectable Cholangiocarcinoma
Yawen Dong, Patrick Starlinger
Hepatology (Baltimore, Md.)
|
March 27, 2014
Role of platelets in systemic tissue protection after remote ischemic preconditioning
Patrick Starlinger, Thomas Gruenberger
Journal of Hepatology
|
March 20, 2018
Reply to: "Intra-platelet serotonin in prognosis of tumorigenesis: Friend or foe?"
David Pereyra, Patrick Starlinger
Annals of Surgical Oncology
|
August 21, 2025
ASO Author Reflections: Real-World Outcomes of Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab for Surgical Conversion of Borderline Resectable Cholangiocarcinoma
Yawen Dong, Patrick Starlinger
Page
of 14